Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + epirubicin + pegfilgrastim
- Development stage
- Phase 3
- Lead developer
- Roche
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
This is a combination therapy consisting of two chemotherapy agents (capecitabine and epirubicin) with a supportive medication (pegfilgrastim). Capecitabine is an oral fluoropyrimidine that is converted to 5-fluorouracil in tumor tissues. Epirubicin is an anthracycline antibiotic that inhibits DNA and RNA synthesis. Together, these agents are used in the treatment of various cancers, particularly breast cancer. Pegfilgrastim is a long-acting form of granulocyte colony-stimulating factor (G-CSF) that stimulates the production of neutrophils to reduce the risk of infection in patients receiving myelosuppressive chemotherapy.
02
Targets
DNACSF3R (Granulocyte colony-stimulating factor receptor)TS (Thymidylate synthase)TOP2A (DNA topoisomerase II)Neuraminidase
Beyond the preview
Go deeper on capecitabine + epirubicin + pegfilgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + epirubicin + pegfilgrastim.